Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Olfactory Neuroblastoma
Posterior reversible encephalopathy syndrome (PRES) is a rare but severe neurological syndrome that may stem from the use of some medications. Although its mechanism is not well-known, hypertension and endothelial dysfunction have been mentioned in previous literature as being related. Lenvatinib se...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Brain Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3425/13/1/33 |
| _version_ | 1797445267551682560 |
|---|---|
| author | Yu-Ju Tseng Chun-Nan Chen Ruey-Long Hong Woon-Man Kung Abel Po-Hao Huang |
| author_facet | Yu-Ju Tseng Chun-Nan Chen Ruey-Long Hong Woon-Man Kung Abel Po-Hao Huang |
| author_sort | Yu-Ju Tseng |
| collection | DOAJ |
| description | Posterior reversible encephalopathy syndrome (PRES) is a rare but severe neurological syndrome that may stem from the use of some medications. Although its mechanism is not well-known, hypertension and endothelial dysfunction have been mentioned in previous literature as being related. Lenvatinib serves as a neoplastic agent that inhibits the tyrosine kinase of vascular endothelial growth factor receptors (VEGFR). VEGFR inhibitors result in endothelial dysfunction and consequent hypertension by nitric oxide pathway suppression and endothelin (ET)-1 stimulation. We hypothesized that VEGFR inhibitors would cause PRES. Herein, we report the case of a 40-year-old man with olfactory neuroblastoma who developed PRES while undergoing treatment with lenvatinib, 7 months after initiation. The symptoms included loss of consciousness and seizures. Fortunately, the symptoms and presence of PRES in imaging resolved, 7 days and 1 month, respectively, after cessation of lenvatinib. |
| first_indexed | 2024-03-09T13:23:19Z |
| format | Article |
| id | doaj.art-5fd0b49feb0e401096bdcc88308a3aac |
| institution | Directory Open Access Journal |
| issn | 2076-3425 |
| language | English |
| last_indexed | 2024-03-09T13:23:19Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Brain Sciences |
| spelling | doaj.art-5fd0b49feb0e401096bdcc88308a3aac2023-11-30T21:26:38ZengMDPI AGBrain Sciences2076-34252022-12-011313310.3390/brainsci13010033Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Olfactory NeuroblastomaYu-Ju Tseng0Chun-Nan Chen1Ruey-Long Hong2Woon-Man Kung3Abel Po-Hao Huang4Department of Pharmacy, National Taiwan University Hospital, Taipei City 100, TaiwanDepartment of Otolaryngology, National Taiwan University Hospital, Taipei City 100, TaiwanDepartment of Oncology, National Taiwan University Hospital, Taipei City 100, TaiwanDepartment of Exercise and Health Promotion, College of Kinesiology and Health, Chinese Culture University, Taipei City 111, TaiwanDepartment of Surgery, National Taiwan University Hospital, Taipei City 100, TaiwanPosterior reversible encephalopathy syndrome (PRES) is a rare but severe neurological syndrome that may stem from the use of some medications. Although its mechanism is not well-known, hypertension and endothelial dysfunction have been mentioned in previous literature as being related. Lenvatinib serves as a neoplastic agent that inhibits the tyrosine kinase of vascular endothelial growth factor receptors (VEGFR). VEGFR inhibitors result in endothelial dysfunction and consequent hypertension by nitric oxide pathway suppression and endothelin (ET)-1 stimulation. We hypothesized that VEGFR inhibitors would cause PRES. Herein, we report the case of a 40-year-old man with olfactory neuroblastoma who developed PRES while undergoing treatment with lenvatinib, 7 months after initiation. The symptoms included loss of consciousness and seizures. Fortunately, the symptoms and presence of PRES in imaging resolved, 7 days and 1 month, respectively, after cessation of lenvatinib.https://www.mdpi.com/2076-3425/13/1/33posterior reversible encephalopathy syndromelenvatinibolfactory neuroblastoma |
| spellingShingle | Yu-Ju Tseng Chun-Nan Chen Ruey-Long Hong Woon-Man Kung Abel Po-Hao Huang Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Olfactory Neuroblastoma Brain Sciences posterior reversible encephalopathy syndrome lenvatinib olfactory neuroblastoma |
| title | Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Olfactory Neuroblastoma |
| title_full | Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Olfactory Neuroblastoma |
| title_fullStr | Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Olfactory Neuroblastoma |
| title_full_unstemmed | Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Olfactory Neuroblastoma |
| title_short | Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Olfactory Neuroblastoma |
| title_sort | posterior reversible encephalopathy syndrome after lenvatinib therapy in a patient with olfactory neuroblastoma |
| topic | posterior reversible encephalopathy syndrome lenvatinib olfactory neuroblastoma |
| url | https://www.mdpi.com/2076-3425/13/1/33 |
| work_keys_str_mv | AT yujutseng posteriorreversibleencephalopathysyndromeafterlenvatinibtherapyinapatientwitholfactoryneuroblastoma AT chunnanchen posteriorreversibleencephalopathysyndromeafterlenvatinibtherapyinapatientwitholfactoryneuroblastoma AT rueylonghong posteriorreversibleencephalopathysyndromeafterlenvatinibtherapyinapatientwitholfactoryneuroblastoma AT woonmankung posteriorreversibleencephalopathysyndromeafterlenvatinibtherapyinapatientwitholfactoryneuroblastoma AT abelpohaohuang posteriorreversibleencephalopathysyndromeafterlenvatinibtherapyinapatientwitholfactoryneuroblastoma |